{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:24:15Z","timestamp":1790709855155,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00108-025-02027-8","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:23:55Z","timestamp":1765358635000},"page":"152-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Orale Antibiotika\u00a0\u2013 auch bei schweren Infektionen?","Oral antibiotics: even in severe infections?"],"prefix":"10.1007","volume":"67","author":[{"given":"Rika","family":"Draenert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2027_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehad193","volume":"00","author":"V Delgade","year":"2023","unstructured":"Delgade\u00a0V et\u00a0al (2023) ESC guidelines for the management of endocarditis. European Heart Journal 00:1\u201395 https:\/\/doi.org\/10.1093\/eurheartj\/ehad193","journal-title":"European Heart Journal"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2018","unstructured":"Iversen\u00a0K et\u00a0al (2018) Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N\u00a0Engl J Med 380:415\u2013424","journal-title":"N Engl J Med"},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMc2114046","volume":"386","author":"MM Pries-Heje","year":"2022","unstructured":"Pries-Heje\u00a0MM et\u00a0al (2022) Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N\u00a0Engl J Med 386:601\u2013602","journal-title":"N Engl J Med"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","volume":"54","author":"H Tissot-Dupont","year":"2019","unstructured":"Tissot-Dupont\u00a0H et\u00a0al (2019) High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. Int J Antimicrob Agents 54:143\u2013148","journal-title":"Int J Antimicrob Agents"},{"key":"2027_CR5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/jac\/dkaf209","volume":"80","author":"Z Tan","year":"2025","unstructured":"Tan\u00a0Z et\u00a0al (2025) Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a\u00a0systematic review and meta-analysis. J\u00a0Antimicrob Chemother 80:2344\u20132360","journal-title":"J Antimicrob Chemother"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijantimicag.2017.12.010","volume":"51","author":"K Diallo","year":"2018","unstructured":"Diallo\u00a0K et\u00a0al (2018) Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey. Int J Antimicrob Agents 51:794\u2013798","journal-title":"Int J Antimicrob Agents"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.ijid.2025.107917","volume":"156","author":"E Rando","year":"2025","unstructured":"Rando\u00a0E et\u00a0al (2025) Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A\u00a0post hoc emulation trial of the SIMPLIFY trial. Int J Infect Dis 156:107917","journal-title":"Int J Infect Dis"},{"key":"2027_CR8","doi-asserted-by":"crossref","unstructured":"Bejon PA et\u00a0al (2019) The OVIVA trial. Lancet Infect Dis 19(1058)","DOI":"10.1016\/S1473-3099(19)30482-7"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"H-K Li","year":"2019","unstructured":"Li\u00a0H\u2011K et\u00a0al (2019) Oral versus Intravenous Antibiotics for Bone and Joint Infection. N\u00a0Engl J Med 380:425\u2013436","journal-title":"N Engl J Med"},{"key":"2027_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s15010-025-02517-9","volume":"53","author":"G Schreiner","year":"2025","unstructured":"Schreiner\u00a0G et\u00a0al (2025) Oral antibiotics demonstrate similar rates of success and complications compared to parenteral antibiotics for bone and joint infections: a\u00a0systematic review and meta-analysis. Infection 53:1899\u20131909","journal-title":"Infection"},{"key":"2027_CR11","unstructured":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2792124"},{"key":"2027_CR12","unstructured":"https:\/\/register.awmf.org\/de\/leitlinien\/detail\/020-020"},{"key":"2027_CR13","first-page":"32","volume":"48","author":"C Cherubin","year":"1986","unstructured":"Cherubin\u00a0C et\u00a0al (1986) Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms. Scand J Infect Dis Suppl 48:32\u201337","journal-title":"Scand J Infect Dis Suppl"},{"key":"2027_CR14","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.1016\/0002-9343(89)90073-9","volume":"87","author":"CE Cox","year":"1989","unstructured":"Cox\u00a0CE (1989) Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. Am J Med 87:S252\u2013S254","journal-title":"Am J Med"},{"key":"2027_CR15","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/0002-9343(89)90050-8","volume":"87","author":"RJ Fass","year":"1989","unstructured":"Fass\u00a0RJ et\u00a0al (1989) Intravenous\/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 87:S164\u2013S168","journal-title":"Am J Med"},{"key":"2027_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ofid\/ofae193","volume":"11","author":"JJ Veillette","year":"2024","unstructured":"Veillette\u00a0JJ et\u00a0al (2024) Real-world effectiveness of intravenous and oral antibiotic stepdown strategies for gram-negative complicated urinary tract infection with bacteremia. Open Forum Infect Dis 11:193","journal-title":"Open Forum Infect Dis"},{"key":"2027_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jgar.2022.12.010","volume":"32","author":"G-L Teng","year":"2023","unstructured":"Teng\u00a0G\u2011L et\u00a0al (2023) Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: A\u00a0systematic review and meta-analysis of randomized controlled trials. J\u00a0Glob Antimicrob Resist 32:88\u201397","journal-title":"J Glob Antimicrob Resist"},{"key":"2027_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00000658-200008000-00016","volume":"232","author":"SM Cohn","year":"2000","unstructured":"Cohn\u00a0SM et\u00a0al (2000) Comparison of intravenous\/oral ciprofloxacin plus metronidazole versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232:254\u2013262","journal-title":"Ann Surg"},{"key":"2027_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00000658-199603000-00012","volume":"223","author":"JS Solomkin","year":"1996","unstructured":"Solomkin\u00a0JS et\u00a0al (1996) Results of a\u00a0randomized trial comparing sequential intravenous\/oral treatment with ciprofloxacin plus metronidazole to imipenem\/cilastatin for intra-abdominal infections. Ann Surg 223:303\u2013315","journal-title":"Ann Surg"},{"key":"2027_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/sur.2006.7.341","volume":"7","author":"H Wacha","year":"2006","unstructured":"Wacha\u00a0H et\u00a0al (2006) Comparison of sequential intravenous\/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect 7:341\u2013354","journal-title":"Surg Infect"},{"key":"2027_CR21","unstructured":"https:\/\/register.awmf.org\/de\/leitlinien\/detail\/030-089"},{"key":"2027_CR22","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1128\/AAC.46.12.3724-3730.2002","volume":"46","author":"M Brunner","year":"2002","unstructured":"Brunner\u00a0M et\u00a0al (2002) Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses. Antimicrob Agents Chemother 46:3724\u20133730","journal-title":"Antimicrob Agents Chemother"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0924-8579(94)90061-2","volume":"4","author":"P Dellamonica","year":"1994","unstructured":"Dellamonica\u00a0P (1994) Cefuroxime axetil. Int J Antimicrob Agents 4:23\u201336","journal-title":"Int J Antimicrob Agents"},{"key":"2027_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00003088-200140001-00003","volume":"40","author":"J Lettieri","year":"2001","unstructured":"Lettieri\u00a0J et\u00a0al (2001) Effect of food on the pharmacokinetics of a\u00a0single oral dose of moxifloxacin 400\u202fmg in healthy male volunteers. Clin Pharmacokinet 40:19\u201325","journal-title":"Clin Pharmacokinet"},{"key":"2027_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/bdd.2510080604","volume":"8","author":"A Finn","year":"1987","unstructured":"Finn\u00a0A et\u00a0al (1987) Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm & Drug Disp 8:519\u2013526","journal-title":"Biopharm & Drug Disp"},{"key":"2027_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199100423-00005","volume":"42","author":"MT Borin","year":"1991","unstructured":"Borin\u00a0MT (1991) A review of the pharmacokinetics of cefpodoxime proxetil. Drugs 42:13\u201321","journal-title":"Drugs"},{"key":"2027_CR27","unstructured":"Fachinfo DoxyHEXAL\u00ae 200\u202fmg tabs (Stand 10\/2023)"},{"issue":"Suppl 1","key":"2027_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200140001-00005","volume":"40","author":"H Stass","year":"2001","unstructured":"Stass\u00a0H et\u00a0al (2001) Effects of dairy products on the oral bioavailability of moxifloxacin, a\u00a0novel 8\u2011methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 40(Suppl 1):33\u201338","journal-title":"Clin Pharmacokinet"},{"key":"2027_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2125.1991.tb05526.x","volume":"31","author":"M Kara","year":"1991","unstructured":"Kara\u00a0M et\u00a0al (1991) Clinical and chemical interactions between iron preparations and ciprofloxacin. Brit J Clinical Pharma 31:257\u2013261","journal-title":"Brit J Clinical Pharma"},{"key":"2027_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/clpt.1989.207","volume":"46","author":"DE Nix","year":"1989","unstructured":"Nix\u00a0DE et\u00a0al (1989) Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 46:700\u2013705","journal-title":"Clin Pharmacol Ther"},{"key":"2027_CR31","volume-title":"Stockley\u2019s Drug Interactions","year":"2025","unstructured":"Baxter\u00a0K et\u00a0al (Hrsg) (2025) Stockley\u2019s Drug Interactions. Pharmaceutical Press, London"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02027-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:01:29Z","timestamp":1769522489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02027-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02027-8","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Draenert, J.\u00a0Bogner und A.\u00a0Weber geben an, dass hinsichtlich des Manuskripts kein Interessenkonflikt besteht. R.\u00a0Draenert ist im Vorstand der Akademie f\u00fcr Infektionsmedizin und im Beirat der Deutschen Gesellschaft f\u00fcr Infektiologie (DGI).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}